Ad
BLUE Quote Trading Chart bluebird bio Inc.
home / stock / blue / blue quote
Quote | bluebird bio Inc. (NASDAQ:BLUE)
| Last: | $0.4224 |
|---|---|
| Change Percent: | 4.3% |
| Open: | $0.41 |
| Close: | $0.405 |
| High: | $0.4347 |
| Low: | $0.406 |
| Volume: | 1,987,910 |
| Last Trade Date Time: | 12/02/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
BLUE Last Twenty Trading Days
| Last | Open | Close | High | Low | Volume | Date |
|---|---|---|---|---|---|---|
| $0.4224 | $0.41 | $0.405 | $0.4347 | $0.406 | 1,987,910 | 12-02-2024 |
| $0.405 | $0.3773 | $0.405 | $0.41 | $0.3701 | 4,706,188 | 11-29-2024 |
| $0.3778 | $0.369 | $0.3778 | $0.387 | $0.36 | 4,276,137 | 11-28-2024 |
| $0.3778 | $0.369 | $0.3778 | $0.387 | $0.36 | 4,276,137 | 11-27-2024 |
| $0.37 | $0.37 | $0.37 | $0.3789 | $0.3471 | 3,380,889 | 11-26-2024 |
| $0.3617 | $0.35 | $0.3617 | $0.41 | $0.35 | 11,387,856 | 11-25-2024 |
| $0.3501 | $0.2985 | $0.3501 | $0.36345 | $0.298 | 10,379,941 | 11-22-2024 |
| $0.2979 | $0.31 | $0.2979 | $0.3139 | $0.29 | 3,872,344 | 11-21-2024 |
| $0.303 | $0.3051 | $0.303 | $0.315899 | $0.29 | 3,452,289 | 11-20-2024 |
| $0.3051 | $0.32 | $0.3051 | $0.33 | $0.302 | 4,796,215 | 11-19-2024 |
| $0.333 | $0.3241 | $0.333 | $0.3365 | $0.315 | 3,560,083 | 11-18-2024 |
| $0.3208 | $0.3655 | $0.3208 | $0.3699 | $0.31885 | 9,162,727 | 11-15-2024 |
| $0.3626 | $0.371 | $0.3626 | $0.395 | $0.345 | 5,670,556 | 11-14-2024 |
| $0.3763 | $0.3906 | $0.3763 | $0.418 | $0.3725 | 4,392,804 | 11-13-2024 |
| $0.3906 | $0.4016 | $0.3906 | $0.4296 | $0.39 | 8,373,422 | 11-12-2024 |
| $0.4053 | $0.42 | $0.4053 | $0.4298 | $0.3971 | 4,515,899 | 11-11-2024 |
| $0.4057 | $0.38 | $0.4057 | $0.419 | $0.38 | 5,976,533 | 11-08-2024 |
| $0.3821 | $0.43 | $0.3821 | $0.43 | $0.3373 | 16,825,870 | 11-07-2024 |
| $0.4394 | $0.4455 | $0.4394 | $0.461 | $0.4319 | 6,570,553 | 11-06-2024 |
| $0.4524 | $0.46 | $0.4524 | $0.4693 | $0.4454 | 6,770,889 | 11-05-2024 |
News, Short Squeeze, Breakout and More Instantly...
Ad
-
- 74 patient starts completed or scheduled to date in 2024 across bluebird’s commercial portfolio - - Third quarter 2024 net revenue of $10.6 million reflects quarter-to-quarter fluctuations in drug product infusions; anticipate at least $25 million of net revenue in the fourth q...
-
bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird bio” or the “Company”) today announced that it partially adjourned its annual meeting of stockholders (“Annual Meeting”) on Wednesday, November 6, 2024, to allow the Company to solicit additional votes to obtai...
-
bluebird bio, Inc. (Nasdaq: BLUE) today announced that new and updated data from its lentiviral vector (LVV) gene addition programs in patients with sickle cell disease who have a history of vaso-occlusive events and patients with beta-thalassemia who require regular blood transfusions will be pr...